21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients

被引：45

作者：

Akashi-Tanaka, Sadako ^{[1
]}

Shimizu, Chikako ^{[2
]}

Ando, Masashi ^{[2
]}

Shibata, Tatsuhiro ^{[3
]}

Katsumata, Noriyuki ^{[2
]}

Kouno, Tsutomu ^{[2
]}

Terada, Kotoe ^{[1
]}

Shien, Tadahiko ^{[1
]}

Yoshida, Miwa ^{[1
]}

Hojo, Takashi ^{[1
]}

Kinoshita, Takayuki ^{[1
]}

Fujiwara, Yasuhiro ^{[2
]}

Yoshimura, Kenichi ^{[4
]}

机构：

[1] Div Breast Surg, Chuo Ku, Tokyo 1040045, Japan

[2] Natl Canc Ctr, Div Med Oncol, Tokyo, Japan

[3] Natl Canc Ctr, Res Inst, Dept Pathol, Tokyo 104, Japan

[4] Kyoto Univ Hosp, Translat Res Ctr, Div Clin Trial Management, Tokyo, Japan

来源：

BREAST | 2009年 / 18卷 / 03期

关键词：

Breast cancer; Multigene assay; Recurrence score; Neoadjuvant endocrine therapy; Predictive factor; TUMOR GENE-EXPRESSION; CHEMOTHERAPY; TAMOXIFEN; WOMEN; ANASTROZOLE; COMBINATION; RECURRENCE; ARIMIDEX;

D O I：

10.1016/j.breast.2009.03.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study examined postmenopausal estrogen receptor-positive breast cancer patients who received prospective neoadjuvant endocrine therapy (NAET) with tamoxifen or anastrozole to determine if the 21-gene recurrence score (RS) predicts NAET responses. RS scores were determined from pretreatment core biopsy specimens. Although half of the specimens yielded insufficient RNA, the remaining samples were highly representative. Patients with a low RS tended to respond better than those with an intermediate or high RS (n = 43). Response rates by RS were similar between the tamoxifen and anastrozole groups. Patients with a low RS tended to have better relapse-free Survival (RFS) than those with ail intermediate or high RS (5y-RFS; 100% vs. 84% and 73%, respectively). These results suggest that RS predicts responses to NAET with tamoxifen or anastrozole. Because this pilot study examined a small sample size, these results should be validated in larger studies. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：171 / 174

页数：4

共 20 条

[1] Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy [J].

Akashi-Tanaka, Sadako ;

Omatsu, Mutsuko ;

Shimizu, Chikako ;

Ando, Masashi ;

Terada, Kotoe ;

Shien, Tadahiko ;

Kinoshita, Takayuki ;

Fujiwara, Yasuhiro ;

Seki, Kunihiko ;

Hasegawa, Tadashi ;

Fukutomi, Takashi .

BREAST, 2007, 16 (05) :482-488

[2] Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute [J].

Bonadonna, G ;

Valagussa, P ;

Brambilla, C ;

Ferrari, L ;

Moliterni, A ;

Terenziani, M ;

Zambetti, M .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :93-100

[3] Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer - The Pre-Operative "Arimidex" Compared to Tamoxilen (PROAC7) trial [J].

Cataliotti, L ;

Buzdar, AU ;

Noguchi, S ;

Bines, J ;

Takatsuka, Y ;

Petrakova, K ;

Dube, P ;

de Oliveira, CT .

CANCER, 2006, 106 (10) :2095-2103

[4] Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients [J].

Chang, Jenny C. ;

Makris, Andreas ;

Gutierrez, M. Carolina ;

Hilsenbeck, Susan G. ;

Hackett, James R. ;

Jeong, Jennie ;

Liu, Mei-Lan ;

Baker, Joffre ;

Clark-Langone, Kim ;

Baehner, Frederick L. ;

Sexton, Krsytal ;

Mohsin, Syed ;

Gray, Tara ;

Alvarez, Laura ;

Chamness, Gary C. ;

Osborne, C. Kent ;

Shak, Steven .

BREAST CANCER RESEARCH AND TREATMENT, 2008, 108 (02) :233-240

[5] Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes [J].

Cobleigh, MA ;

Tabesh, B ;

Bitterman, P ;

Baker, J ;

Cronin, M ;

Liu, ML ;

Borchik, R ;

Mosquera, JM ;

Walker, MG ;

Shak, S .

CLINICAL CANCER RESEARCH, 2005, 11 (24) :8623-8631

[6] Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors:: A study of preoperative treatment [J].

Colleoni, M ;

Viale, G ;

Zahrieh, D ;

Pruneri, G ;

Gentilini, O ;

Veronesi, P ;

Gelber, RD ;

Curigliano, G ;

Torrisi, R ;

Luini, A ;

Intra, M ;

Galimberti, V ;

Renne, G ;

Nolè, F ;

Peruzzotti, G ;

Goldhirsch, A .

CLINICAL CANCER RESEARCH, 2004, 10 (19) :6622-6628

[7] Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial [J].

Ellis, MJ ;

Coop, A ;

Singh, B ;

Mauriac, L ;

Llombert-Cussac, A ;

Jänicke, F ;

Miller, WR ;

Evans, DB ;

Dugan, M ;

Brady, C ;

Quebe-Fehling, E ;

Borgs, M .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) :3808-3816

[8] Effect of preoperative chemotherapy on the outcome of women with operable breast cancer [J].

Fisher, B ;

Bryant, J ;

Wolmark, N ;

Mamounas, E ;

Brown, A ;

Fisher, ER ;

Wickerham, DL ;

Begovic, M ;

DeCillis, A ;

Robidoux, A ;

Margolese, RG ;

Cruz, AB ;

Hoehn, JL ;

Lees, AW ;

Dimitrov, NV ;

Bear, HD .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2672-2685

[9] Histopathologic variables predict Oncotype DX™ Recurrence Score [J].

Flanagan, Melina B. ;

Dabbs, David J. ;

Brufsky, Adam M. ;

Beriwal, Sushil ;

Bhargava, Rohit .

MODERN PATHOLOGY, 2008, 21 (10) :1255-1261

[10] Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer [J].

Gianni, L ;

Zambetti, M ;

Clark, K ;

Baker, J ;

Cronin, M ;

Wu, J ;

Mariani, G ;

Rodriguez, J ;

Carcangiu, M ;

Watson, D ;

Valagussa, P ;

Rouzier, R ;

Symmans, WF ;

Ross, JS ;

Hortobagyi, GN ;

Pusztai, L ;

Shak, S .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (29) :7265-7277

← 1 2 →